search button
Open Access

Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis

  • Authors:
    • Shanshan Liu
    • Bi Yin
    • Bo Wu
    • Zhixing Fan

  • View Affiliations

  • Published online on: April 21, 2022     https://doi.org/10.3892/etm.2022.11333
  • Article Number: 406

  • Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

To evaluate the effects and safety of sacubitril/valsartan in patients with acute myocardial infarction (AMI), a total of four databases, including PubMed, Cochrane Library, Embase and Web of Science, and the ClinicalTrials.gov website were searched. Using a combination of medical subject headings and entry terms, the final search was performed in July 2021. A manual search of cross‑references from the original articles was also conducted. The meta‑analysis was subsequently performed with Revman 5.3 software and a total of four studies comprising 586 patients were included. The results disclosed a significant reduction in major adverse cardiovascular and cerebrovascular events (MACCEs) [odds ratio (OR), 0.47; 95% confidence interval (CI), 0.30‑0.73; P=0.0007], readmission (OR, 0.45; 95% CI, 0.29‑0.71; P=0.0006), incidence of acute heart failure (AHF) (OR, 0.45; 95% CI, 0.28‑0.71; P=0.0007) and N‑terminal pro B‑type natriuretic peptide [standardized mean difference (SMD), ‑0.88; 95% CI, ‑1.55‑(‑0.21); P=0.01] in the sacubitril/valsartan group compared with that in the control group, and a random effects model was used to pool these data. No significant differences were identified in the incidence of hypotension (OR, 2.91; 95% CI, 0.55‑15.51; P=0.21), adverse events (OR, 2.19; 95% CI, 0.42‑11.37; P=0.35), left ventricular ejection fraction (mean difference, 1.96; 95% CI, ‑0.84‑4.76; P=0.17) or soluble suppression of tumorigenesis‑2 (SMD, ‑0.45; 95% CI, ‑1.62‑0.71; P=0.45) according to the random effects model.In conclusion, the present meta‑analysis revealed that sacubitril/valsartan was able to effectively reduce the incidence of MACCEs, readmission and AHF in patients with AMI after revascularization without any obvious adverse events.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Liu S, Yin B, Wu B and Fan Z: Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis. Exp Ther Med 23: 406, 2022
APA
Liu, S., Yin, B., Wu, B., & Fan, Z. (2022). Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis. Experimental and Therapeutic Medicine, 23, 406. https://doi.org/10.3892/etm.2022.11333
MLA
Liu, S., Yin, B., Wu, B., Fan, Z."Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis". Experimental and Therapeutic Medicine 23.6 (2022): 406.
Chicago
Liu, S., Yin, B., Wu, B., Fan, Z."Protective effect of sacubitril/valsartan in patients with acute myocardial infarction: A meta‑analysis". Experimental and Therapeutic Medicine 23, no. 6 (2022): 406. https://doi.org/10.3892/etm.2022.11333